Lactose-free, non-hyproscopic and anhydrous pharmaceutical compositions of descarboethoxyloratadine

A technology of desethoxycarbonyl loratadine and ethoxycarbonyl loratadine, applied in the field of desethoxycarbonyl loratadine pharmaceutical composition

Inactive Publication Date: 2000-03-08
SEPACOR INC
View PDF3 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Another disadvantage of both astemizole and loratadine is that the respective drugs are associated with the growth of melanoma and fibrosarcoma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0089] Compressed DCL tablets may be prepared by conventional wet granulation techniques such that individual dosage units contain 0.1 mg to 10 mg of DCL.

[0090] Per tablet Per 10,000 tablets DCL 10mg 100g Starch 60mg 600g Talc 12mg 120g Gum Arabic 12mg 120g Stearic Acid 1mg 10g

[0091] Mix gum arabic with equal weight of starch to form a paste, and use the paste for DCL granulation. The mixture is dried and sieved. Add remaining ingredients and mix thoroughly. The resulting mixture was compressed into tablets using 9 / 32 inch (7 mm) punches. Example 2

Embodiment 2

[0092] Compressed DCL tablets can be prepared using conventional dry granulation techniques, with each dosage unit containing 0.1 mg to 10 mg of DCL.

[0093] Each tablet DCL 10mg 100g starch 85mg 850g per 10,000 tablets

[0094] The starch was dried to 10% moisture and then thoroughly mixed with the DCL. The resulting mixture is compressed into chips, which are then ground into fine particles. The resulting mixture was compressed into tablets using 9 / 32 inch (7 mm) punches. Example 3

Embodiment 3

[0095] Compressed DCL tablets may be prepared using conventional direct compression techniques such that individual dosage units contain 0.1 mg to 10 mg of DCL.

[0096] Per tablet DCL 10mg 100g microcrystalline cellulose 80mg 800g stearic acid 5mg 50g colloidal silicon dioxide 1mg 10g per 10,000 tablets

[0097] All ingredients are mixed in a suitable mixer. The resulting mixture was compressed into tablets using 9 / 32 inch (7 mm) punches. Example 4

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
Login to view more

Abstract

Stable pharmaceutical compositions of descarboethoxyloratadine (DCL), a metabolic derivative of loratadine, for the treatment of allergic rhinitis and other histamine-induced disorders are disclosed. The compositions are formulated to avoid the incompatibility between DCL and reactive excipients such as lactose and other mono- and di-saccharides. Disclosed compositions include lactose-free, non-hygroscopic and anhydrous stable pharmaceutical compositions of DCL.

Description

[0001] Cross references to related patent applications [0002] This application claims the priority of U.S. provisional patent applications 60 / 053,050 (applied on July 21, 1997), 60 / 045,184 (applied on April 30, 1997) and 60 / 037,325 (applied on February 7, 1997). Background of the invention [0003] The present invention relates to 8-chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine, known as Pharmaceutical compositions of descarboethoxyloratadine (DCL). [0004] Desethoxycarbonylloratadine [0005] DCL is a metabolic derivative of Loratadine, an H-1 histamine receptor antagonist. H-1 histamine receptor antagonists mediate the antagonistic response of conventional antihistamines. The antihistamine activity of loratadine is comparable to that of terfenadine and astemizole, and on a milligram-for-mg basis, it is four times more potent than fenadine in suppressing allergic bronchospasm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D401/04A61KA61K9/14A61K9/20A61K31/395A61K31/445A61K31/4545A61K31/60A61P11/02A61P17/04A61P27/02A61P27/16A61P29/00A61P37/08A61P43/00
CPCA61K31/16A61K9/2013A61K9/2054A61K31/60A61K31/4545A61K9/2018A61K31/621A61K31/445A61K9/2009A61K9/2059A61K31/473A61P11/00A61P11/02A61P11/06A61P17/00A61P17/04A61P27/00A61P27/02A61P27/16A61P29/00A61P37/00A61P37/06A61P37/08A61P43/00A61K2300/00
Inventor 马丁·P·雷德蒙哈尔·T·巴特勒斯蒂芬·A·沃尔德保罗·D·鲁宾
Owner SEPACOR INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap